A major new review has found that certain psychiatric medications are linked to a significantly lower risk of suicide and self-harm in people living with serious mental health conditions. The findings, drawn from data covering more than 6 million individuals across 13 countries, offer some of the clearest real-world evidence yet that the right medication, matched to the right diagnosis, may play a meaningful role in suicide prevention. The findings were published in eClinicalMedicine.
The research, led by psychiatrists at the University of Oxford, pooled results from 48 observational studies conducted over three decades. Rather than relying on controlled clinical trials, which often exclude the very patients most at risk of suicidal behaviour, the review drew on data from clinical practice, giving it greater relevance to everyday psychiatry.
For people with schizophrenia spectrum disorders, second-generation antipsychotic medications showed the most consistent protective effects. Clozapine was associated with a 60% reduction in suicide mortality, while olanzapine and quetiapine also showed meaningful reductions. Risperidone was linked to lower risks of both suicide attempts and suicide death.
In bipolar disorder, lithium emerged as one of the most protective treatments, with strong associations with reduced suicide risk across multiple studies. Valproic acid also showed a link with lower suicide mortality, though the researchers noted that current clinical guidelines caution against its use because of concerns over long-term side effects.
For people with depression, both selective serotonin reuptake inhibitors and older tricyclic antidepressants were associated with reduced risk of suicide death. The findings provide real-world support for the use of antidepressants in managing suicide risk in depressive illness, complementing and in some respects extending the evidence from clinical trials.
Not all findings were reassuring. Benzodiazepines, a class of medications commonly prescribed for anxiety and sleep disorders, were associated with a higher risk of suicide mortality across most diagnostic categories, including schizophrenia, bipolar disorder, and personality disorders. The authors suggest that people prescribed these medications should receive regular clinical reviews.
The researchers were careful to stress that the findings do not prove cause and effect. Observational studies are subject to confounding, meaning that patients prescribed certain medications may differ from those who are not in ways that influence outcomes independently of the treatment itself. Publication bias was also identified for some findings, particularly around lithium and clozapine, suggesting that studies reporting favourable results may be more likely to be published.
Despite these limitations, the review represents one of the most comprehensive assessments of how psychiatric medication affects suicide risk in real clinical populations. The authors argue that personalising medication choices based on a patient’s specific diagnosis should be considered a central component of suicide prevention strategies, alongside psychological support and social interventions.
The study reinforces that suicide prevention in mental health requires a joined-up approach, where pharmacological treatment is one carefully chosen tool among many.